Why Choose Us

Advanced Equipment

Our company has advanced production equipment, complete product testing methods, and quality assurance systems, and currently holds ISO/SGS/FDA/GMP/HALA certificates.

Quality Control

Using high-quality materials and establishing a strict quality control system, assigning specific persons in charge of each part of production, from raw material procurement to assembly.

Professional Team

The researchers employed have 15 years of working experience in the plant extraction industry. A range of new products is released every month.

Competitive Price

The company may offer competitive pricing compared to their competitors, making them a more attractive option to budget-conscious customers.

What Are TAK-653 Capsules?

TAK-653

TAK-653 (also known as Osavampator) is a novel AMPA Positive Allosteric Modulator (AMPA PAM) originally developed by Takeda Pharmaceutical Company for research into major depressive disorder (MDD), cognitive enhancement, and neuroplasticity-related applications.

Its primary mechanism is enhancing glutamate signaling in the brain by positively modulating AMPA receptors, which may help support:

Neuroplasticity
BDNF (Brain-Derived Neurotrophic Factor) release
mTOR pathway activation
Learning and memory
Mood regulation

Unlike traditional , TAK-653 does not directly force receptor activation. Instead, it amplifies natural neuronal signaling, which may provide a wider safety margin and improved tolerability.

Key Benefits of TAK-653 capsule

1. Rapid-Acting Antidepressant Potential

Preclinical studies suggest TAK-653 may produce ketamine-like rapid antidepressant effects, including:

Improved motivation
Enhanced emotional responsiveness
Reduction in anhedonia symptoms

Potential advantages compared to ketamine:

No obvious hallucinogenic effects
Lower dissociative risk
Potentially reduced abuse liability

2. Cognitive Enhancement Support

Research indicates TAK-653 may help support:

Working memory
Executive function
Attention span
Cognitive flexibility

Human studies have shown improvements in certain cognitive performance tests, including the Stroop Test.

3. Neuroplasticity Promotion

TAK-653 has been associated with increased:

BDNF expression
Synaptic formation
Long-Term Potentiation (LTP)

These processes are essential for learning, memory consolidation, and emotional resilience.

4. Advanced Nootropic Interest

Within the advanced nootropic community, TAK-653 is often discussed for its potential role in supporting:

Mental clarity
Learning efficiency
Focus and concentration
Creative thinking
Psychological resilience

TAK-653 capsule Mechanism of Action

TAK-653 primarily works through AMPA receptor modulation:

AMPA Receptor Activation→BDNF↑→mTOR Signaling↑→Synaptic Plasticity↑

Enhances AMPA receptor signaling

Improves neuronal communication efficiency

Supports synaptic plasticity

May improve cognition and mood-related pathways

Suggested TAK-653 Dosage (Research Purposes Only)

⚠ TAK-653 is not FDA-approved for medical use. The following information is based on publicly available research and community discussion and is not medical advice.

Common Research Dosage Ranges

Research Stage Typical Dosage
Beginner Range 0.5mg – 1mg
Common Research Range 1mg – 3mg
Higher Research Range 4mg – 6mg

Human research trials have commonly evaluated:

0.5mg
6mg

Some nootropic communities report:

1.5mg – 2.5mg may provide noticeable cognitive effects.

Potential Side Effects of TAK-653

Current human safety data remains limited, but reported side effects may include:

Commonly Reported Reactions

Mild headache
Insomnia
Nervous stimulation
Nausea
Irritability
Reduced sleep quality

Potential High-Dose Risks

Because TAK-653 enhances glutamatergic signaling, excessive stimulation could theoretically increase risk for:

Anxiety
Overexcitation
Excitotoxicity
Seizure susceptibility in sensitive individuals

However, TAK-653 was specifically designed to reduce the excessive activation issues commonly associated with earlier ampakines.

FAQ

Q: What is TAK-653?

A:TAK-653 is an experimental drug primarily being investigated as a potential treatment for treatment-resistant depression (TRD) and major depressive disorder (MDD). It is a novel compound that functions as a selective positive allosteric modulator (PAM) of the AMPA receptor in the brain.

Q: How does TAK-653 work (mechanism of action)?

A: Unlike other modulators, TAK-653 is unique because it has virtually no direct agonistic (activating) activity on its own. Instead, it binds to the AMPA receptor only when the natural neurotransmitter glutamate is already present. It then potentiates (enhances) the glutamate signal by slowing the rate of receptor desensitization, leading to increased synaptic transmission. This refined mechanism is what gives TAK-653 its potential for both antidepressant and cognitive-enhancing effects without some of the severe side effects of broader-acting compounds.

Q: What are the potential benefits (antidepressant and cognitive)?

A: Antidepressant Effect: In a Phase 2 clinical trial, TAK-653 showed a clinically meaningful and statistically significant improvement in depression severity compared to a placebo. The 1 mg dose led to a significant change (improvement of −6.9 points on the MADRS scale, nominal p=0.0018) after 8 weeks of once-daily oral administration.

Cognitive Enhancement: Preclinical studies suggest that TAK-653 can improve both working memory and recognition memory. In humans, it has been shown to have a "psychostimulant-like" pharmacodynamic profile, improving alertness, visuomotor coordination, and sustained attention in healthy volunteers

Q: What is the dosage of TAK-653?

A:The dosage of TAK-653 varies depending on the study stage and purpose:

Clinical Research: In clinical trials, the dosages that have been researched range from 0.5 mg to 6 mg. For treating depression, a common target dose in studies is up to 6 mg, reached through a titration schedule. One study specifically tested 1 mg and 3 mg doses and found the 1 mg dose to be the most effective.

Research Chemical: In a laboratory setting, it is available for purchase in various amounts (e.g., 1 mg, 5 mg, 10 mg, etc.) strictly for in-vitro research and compound screening, not for human consumption.

Q: What are the side effects and safety profile of TAK-653?

A: TAK-653 has demonstrated a favorable safety and tolerability profile in research to date. Unlike a drug like ketamine, which it is often compared to, TAK-653 did not produce a "hyperlocomotor" response in animal models, a behavior associated with potential psychotomimetic (psychosis-like) side effects in humans. In human trials, it is generally well-tolerated, with reported adverse events being generally similar to those in the placebo group. Most common adverse events were headaches, with no deaths or serious adverse events (SAEs) reported in a major Phase 2 study.

TAK-653 represents a next-generation AMPA receptor modulator designed to support cognitive flexibility, neuroplasticity, and mood-related pathways through advanced glutamatergic signaling research.

With growing interest in rapid-acting neuroplasticity compounds, TAK-653 has become one of the most discussed investigational molecules in the modern neuroscience and nootropic community.

Hot Tags: tak-653 capsule, China tak-653 capsule manufacturers, suppliers, factory